Biocon extended its winning run on Thursday, rising as much as 3.9 per cent to a day’s high of Rs 422.60 against its previous close of Rs 406.35. The stock has surged nearly 10 per cent over the past two sessions, fuelled by its Q2 FY26 performance, and is up 20 per cent over the past month. Advertisement

The pharma major delivered a solid second quarter, with revenue increasing about 20 per cent year-on-year to Rs 4,296 crore. EBITDA rose around 20–22 per cent YoY, while margins held steady at roughly 19 per cent. The company also swung back to profit from a loss in the year-ago period.

Growth was powered by strong traction in both the Biosimilars and Generics divisions. The Biosimilars vertical led the charge with a robust 25 per cent YoY jump, supported by market share gains and a st

See Full Page